Alector raises $133M to push neuro-immunology drugs into Alzheimer’s trials

Previous Fierce 15 winner Alector has raised $133 million through a fifth round of venture capital financing, with plans to move at least three of its immune-modulating drugs into clinical testing against neurodegenerative disorders within the next year, including in Alzheimer’s disease and dementia.

The South San Francisco-based company also unveiled the first three targets for its pipeline, including two immune system receptors used in the brain: TREM2 and SIGLEC-3, which can act as the accelerator or the brake, respectively, on the body’s microglial response and clearance of beta amyloid proteins.

Alector’s hypothesis contends that a dysfunctional immune system can be linked to higher risks of Alzheimer’s disease and frontotemporal dementia, and the company hopes its immuno-neurology drugs will provide as much benefit as similar therapies have shown in cancer.

Read the full story at Fierce Biotech